Key result
Benralizumab resolves life-threatening eosinophilic myocarditis relapse in a patient with EGPA.
Why the study?
Eosinophilic granulomatosis with polyangiitis (EGPA) has unclear pathophysiology with different phenotypes that may respond differently to treatments, including benralizumab.
Case Report (n=1)
Benralizumab may be an effective treatment for eosinophilic myocarditis relapses in patients with EGPA.
Should not change practice after one case; hypothesis-generating for benralizumab in EGPA myocarditis.
Eosinophilic granulomatosis with polyangiitis (EGPA) is characterised by many features, including asthma, allergic rhinitis, peripheral and tissue eosinophilia, and vasculitis. Its pathophysiology is still unclear and we suggest that there are different phenotypes of EGPA, which may respond differently to available treatments. Within the most promising targeting biotherapy, benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, has proved both highly effective and safe. We report herewith a case of EGPA presenting a myocarditis relapse successfully treated with benralizumab.
No takes yet. Share an insight, caveat, or question.
Belfeki et al. (2021) conducted a case report in Eosinophilic granulomatosis with polyangiitis (EGPA) with eosinophilic myocarditis (n=1). Benralizumab was evaluated on Clinical and biological improvement (resolution of symptoms, normalization of cardiac enzymes and eosinophil count). Benralizumab successfully treated a life-threatening eosinophilic myocarditis relapse in a patient with eosinophilic granulomatosis with polyangiitis, normalizing cardiac enzymes and eosinophils.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: